<DOC>
	<DOCNO>NCT01363232</DOCNO>
	<brief_summary>This open label , dose finding , phase Ib clinical trial determine maximum tolerate dose ( MTD ) and/or recommend phase II dose ( RP2D ) orally administer phosphatidylinositol 3'-kinase ( PI3K ) inhibitor BKM120 combination MEK1/2 inhibitor MEK162 . This combination explore patient epidermal growth factor receptor ( EGFR ) mutant non-small cell lung cancer ( NSCLC ) progress EGFR inhibitor triple negative breast cancer , well pancreatic cancer , colorectal cancer , malignant melanoma , NSCLC , advance solid tumor KRAS , NRAS , and/or BRAF mutation . Dose escalation guide Bayesian logistic regression model overdose control . At MTD RP2D , two expansion arm open order ass safety preliminary anti-tumor activity combination BKM120 MEK162 . Study drug administer daily orally continuous schedule . A treatment cycle define 28 day .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics BKM120 Plus MEK162 Selected Advanced Solid Tumor Patients</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically/ cytologically confirm , advance non resectable solid tumor Measurable nonmeasurable , evaluable disease determine RECIST Patients primary CNS tumor CNS tumor involvement . Diabetes mellitus Unacceptable ocular/retinal condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>BKM120</keyword>
	<keyword>MEK162</keyword>
	<keyword>RAS RAF mutation</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>pancreatic cancer , ovarian cancer</keyword>
	<keyword>NSCLC progress EGFR TKI</keyword>
	<keyword>PI3K inhibitor</keyword>
	<keyword>MEK inhibitor</keyword>
</DOC>